Determination and therapeutic exploitation of Ebola virus spontaneous mutation frequency

Journal of Virology

Volumn 90, Issue 5, 2016, Pages 2345-2355

  Alfson, Kendra J ^a   Worwa, Gabriella ^a   Carrion, Ricardo ^a   Griffiths, Anthony ^a  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; RIBAVIRIN; ANTIVIRUS AGENT; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUSE OF DEATH; CELL CULTURE; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEMALE; GENETIC VARIABILITY; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS MUTATION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DNA SEQUENCE; GENETIC VARIATION; GENETICS; HEMORRHAGIC FEVER, EBOLA; HIGH THROUGHPUT SEQUENCING; HUMAN; MACACA FASCICULARIS; MICROBIAL SENSITIVITY TEST; MUTATION RATE; REPORTER GENE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; FEMALE; GENES, REPORTER; GENETIC VARIATION; GREEN FLUORESCENT PROTEINS; HEMORRHAGIC FEVER, EBOLA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INHIBITORY CONCENTRATION 50; MACACA FASCICULARIS; MALE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTATION RATE; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84961140423     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02701-15     Document Type: Article

References (48)

1. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S. 2014. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371:1418-1425. http://dx.doi.org/10.1056/NEJMoa1404505.
2. Feldmann H, Sanchez A, Geisbert TW. 2013. Filoviridae: Marburg and Ebola viruses, Chapter 32, p 923-924. In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Sala M, Wain-Hobson S. 1999. Drift and conservatism in RNA virus evolution: are they adapting or merely changing, Chapter 6. In Domingo E, Webster R, Holland J (ed), Origin and evolution of viruses. Academic Press, San Diego, CA.
4. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A, Bressler D, Williams AJ, Rowe AK, Bertolli J, Khan AS, Ksiazek TG, Peters CJ, Nichol ST. 1999. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S170-S176. http://dx.doi.org/10.1086/514291.
5. Hoenen T, Safronetz D, Groseth A, Wollenberg KR, Koita OA, Diarra B, Fall IS, Haidara FC, Diallo F, Sanogo M, Sarro YS, Kone A, Togo ACG, Traore A, Kodio M, Dosseh A, Rosenke K, de Wit E, Feldmann F, Ebihara H, Munster VJ, Zoon KC, Feldmann H, Sow S. 2015. Virology mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 348:117-119. http://dx.doi.org/10.1126/science.aaa5646.
6. Gire SK, Goba A, Andersen KG, Sealfon RSG, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S, Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang P-P, Nekoui M, Colubri A, Coomber MR, Fonnie M, Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Jalloh AA, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W, Massally JLB, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin JS, Lander ES, Happi C, Gevao SM, Gnirke A, Rambaut A, Garry RF, Khan SH, Sabeti PC. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369-1372. http://dx.doi.org/10.1126/science.1259657.
7. Castilletti C, Carletti F, Gruber CEM, Bordi L, Lalle E, Quartu S, Meschi S, Lapa D, Colavita F, Chiappini R, Mazzarelli A, Marsella P, Petrosillo N, Nicastri E, Chillemi G, Valentini A, Desideri A, Di Caro A, Ippolito G, Capobianchi MR. 2015. Molecular characterization of the first Ebola virus isolated in Italy, from a health care worker repatriated from Sierra Leone. Genome Announc 3:e00639-15. http://dx.doi.org/10.1128/genomeA.00639-15.
8. Kugelman JR, Sanchez-Lockhart M, Andersen KG, Gire S, Park DJ, Sealfon R, Lin AE, Wohl S, Sabeti PC, Kuhn JH, Palacios GF. 2015. Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. mBio 6:e02227-14. http://dx.doi.org/10.1128/mBio.02227-14.
9. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delicat A, Paweska JT, Gonzalez JP, Swanepoel R. 2005. Fruit bats as reservoirs of Ebola virus. Nature 438:575-576. http://dx.doi.org/10.1038/438575a.
10. Marsh GA, Haining J, Robinson R, Foord A, Yamada M, Barr JA, Payne J, White J, Yu M, Bingham J, Rollin PE, Nichol ST, Wang L-F, Middleton D. 2011. Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis 204:S804-S809. http://dx.doi.org/10.1093/infdis/jir300.
11. Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, Rollin PE, Zaki SR, Peters CJ. 1996. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 2:321-325. http://dx.doi.org/10.3201/eid0204.960407.
12. Towner JS, Amman BR, Sealy TK, Carroll SAR, Comer JA, Kemp A, Swanepoel R, Paddock CD, Balinandi S, Khristova ML, Formenty PBH, Albarino CG, Miller DM, Reed ZD, Kayiwa JT, Mills JN, Cannon DL, Greer PW, Byaruhanga E, Farnon EC, Atimnedi P, Okware S, Katongole-Mbidde E, Downing R, Tappero JW, Zaki SR, Ksiazek TG, Nichol ST, Rollin PE. 2009. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 5:e1000536. http://dx.doi.org/10.1371/journal.ppat.1000536.
13. Martina BEE, Osterhaus ADME. 2009. "Filoviruses": a real pandemic threat? EMBO Mol Med 1:10-18. http://dx.doi.org/10.1002/emmm.200900005.
14. Miranda MEG, Miranda NLJ. 2011. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 204:S757-S760. http://dx.doi.org/10.1093/infdis/jir296.
15. Dowall SD, Matthews DA, Garcia-Dorival I, Taylor I, Kenny J, Hertz-Fowler C, Hall N, Corbin-Lickfett K, Empig C, Schlunegger K, Barr JN, Carroll MW, Hewson R, Hiscox JA. 2014. Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity. Genome Biol 15:540. http://dx.doi.org/10.1186/s13059-014-0540-x.
16. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad SciUS A 98:6895-6900. http://dx.doi.org/10.1073/pnas.111085598.
17. Graci JD, Cameron CE. 2006. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16:37-48. http://dx.doi.org/10.1002/rmv.483.
18. Crotty S, Maag D, Arnold JJ, Zhong WD, Lau JYN, Hong Z, Andino R, Cameron CE. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:1375-1379. http://dx.doi.org/10.1038/82191.
19. Huggins J, Zhang ZX, Bray M. 1999. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 179:S240-S247. http://dx.doi.org/10.1086/514316.
20. Huggins JW. 1989. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 11:S750-S761. http://dx.doi.org/10.1093/clinids/11.Supplement_4.S750.
21. Ölschläger S, Neyts J, Günther S. 2011. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res 91:89-93. http://dx.doi.org/10.1016/j.antiviral.2011.05.006.
22. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972. http://dx.doi.org/10.1038/nature04082.
23. Cuevas JM, González-Candelas F, Moya A, Sanjuán R. 2009. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol 83:5760-5764. http://dx.doi.org/10.1128/JVI.00201-09.
24. Young K-C, Lindsay KL, Lee K-J, Liu W-C, He J-W, Milstein SL, Lai MMC. 2003. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38:869-878. http://dx.doi.org/10.1002/hep.1840380413.
25. Mardani M, Jahromi MK, Naieni KH, Zeinali M. 2003. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 36:1613-1618. http://dx.doi.org/10.1086/375058.
26. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
27. Sun Y, Carrion R, Jr, Ye L, Wen Z, Ro Y-T, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, Yang C. 2009. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383:12-21. http://dx.doi.org/10.1016/j.virol.2008.09.020.
28. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178:651-661. http://dx.doi.org/10.1086/515386.
29. Alfson KJ, Beadles MW, Griffiths A. 2014. A new approach to determining whole viral genomic sequences including termini using a single deep sequencing run. J Virol Methods 208:1-5. http://dx.doi.org/10.1016/j.jviromet.2014.07.023.
30. Shurtleff A, Biggins J, Keeney A, Zumbrun E, Bloomfield H, Kuehne A, Audet J, Alfson K, Griffiths A, Olinger G, Bavari S. 2012. Standardization of the filovirus plaque assay for use in preclinical studies. Viruses 4:3511-3530. http://dx.doi.org/10.3390/v4123511.
31. Ebihara H, Theriault S, Neumann G, Alimonti JB, Geisbert JB, Hensley LE, Groseth A, Jones SM, Geisbert TW, Kawaoka Y, Feldmann H. 2007. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 196(Suppl 2): S313-S322. http://dx.doi.org/10.1086/520590.
32. Sanjuán R, Nebot MR, Chirico N, Mansky LM. 2010. Viral mutation rates. J Virol 84:9733-9748. http://dx.doi.org/10.1128/JVI.00694-10.
33. Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, Martín V. 2011. Ribavirin can be mutagenic for arenaviruses. J Virol 85:7246-7255. http://dx.doi.org/10.1128/JVI.00614-11.
34. Airaksinen A, Pariente N, Menéndez-Arias L, Domingo E. 2003. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311:339-349. http://dx.doi.org/10.1016/S0042-6822(03)00144-2.
35. Lanford RE, Chavez D, Guerra B, Lau JYN, Hong Z, Brasky KM, Beames B. 2001. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 75:8074-8081. http://dx.doi.org/10.1128/JVI.75.17.8074-8081.2001.
36. Barnard DL, Bischofberger N, Kim CU. 1997. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses. Antivir Chem Chemother 8:223-233. http://dx.doi.org/10.1177/095632029700800306.
37. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347-2370. http://dx.doi.org/10.1016/S0002-9440(10)63591-2.
38. Carrion R, Ro Y, Hoosien K, Ticer A, Brasky K, de la Garza M, Mansfield K, Patterson JL. 2011. A small nonhuman primate model for filovirus-induced disease. Virology 420:117-124. http://dx.doi.org/10.1016/j.virol.2011.08.022.
39. Tam RC, Lau JY, Hong Z. 2001. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 12:261-272. http://dx.doi.org/10.1177/095632020101200501.
40. Morfin F, Dupuis-Girod S, Frobert E, Mundweiler S, Carrington D, Sedlacek P, Bierings M, Cetkovsky P, Kroes ACM, van Tol MJD, Thouvenot D. 2009. Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone. Antivir Ther 14:55-61.
41. Rusnak JM. 2011. Experience with ribavirin for treatment and postexposure prophylaxis of hemorrhagic fever viruses: Crimean Congo hemorrhagic fever, Lassa fever, and hantaviruses. Appl Biosaf 16:67-87.
42. Bente D, Gren J, Strong JE, Feldmann H. 2009. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2:12-17. http://dx.doi.org/10.1242/dmm.000471.
43. Ignat'ev GM, Strel'tsova MA, Agafonov AP, Kashentseva EA, Prozorovskiĭ NS. 1996. Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, and homologous interferon. Vopr Virusol 41:206-209.
44. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Do Kim Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53. http://dx.doi.org/10.1038/nature13777.
45. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, Rollin PE. 2004. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78:10370-10377. http://dx.doi.org/10.1128/JVI.78.19.10370-10377.2004.
46. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, Lee WF, Spiropoulou CF, Ksiazek TG, Lukwiya M, Kaducu F, Downing R, Nichol ST. 2004. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78:4330-4341. http://dx.doi.org/10.1128/JVI.78.8.4330-4341.2004.
47. Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF. 2015. Emergence of Ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail. Cell Rep 12:2111-2120. http://dx.doi.org/10.1016/j.celrep.2015.08.038.
48. Fowler RA, Fletcher T, Fischer WA, Lamontagne F, Jacob S, Brett-Major D, Lawler JV, Jacquerioz FA, Houlihan C, O'Dempsey T, Ferri M, Adachi T, Lamah M-C, Bah EI, Mayet T, Schieffelin J, McLellan SL, Senga M, Kato Y, Clement C, Mardel S, Vallenas Bejar De Villar RC, Shindo N, Bausch D. 2014. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 190:733-737. http://dx.doi.org/10.1164/rccm.201408-1514CP.